PUBLISHER: KBV Research | PRODUCT CODE: 1309553
PUBLISHER: KBV Research | PRODUCT CODE: 1309553
North America Opioid Use Disorder (OUD) Market Size, Share & Industry Trends Analysis Report By Drug Class (Buprenorphine, Methadone and Naltrexone), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2030
The North America Opioid Use Disorder (OUD) Market would witness market growth of 9.3% CAGR during the forecast period (2023-2030).
Opioids are a kind of medicine used to relax muscles, lessen pain, and reduce stress. Opioid use disorder is a long-lasting, recurring brain disorder distinguished by excessive opioid use. It is categorized as a neurological disorder because it involves functional changes to brain circuits involved in motivation, stress, self-control, and decision-making and because these changes may last for a long period after drug use has stopped. Opioid use disorder is characterized by an intense desire to use opioids, increased opioid tolerance, and withdrawal symptoms after ceasing consumption. Many governments, like the U.S., have implemented measures to effectively handle this condition to lessen the risk. Along with the increasing number of new products being released by large corporations, these legislative changes are projected to positively affect the market.
The U.S. Food and Drug Administration (FDA) has already authorized the safe and highly effective drugs methadone, buprenorphine, and extended-release naltrexone to treat OUD. By easing withdrawal symptoms and decreasing opioid cravings, these medications decrease the likelihood that people with OUD would resume drug use and lessen the chance of a fatal overdose. These drugs also aid in functional recovery, quality-of-life enhancement, and integration into families and communities. These drugs save lives because they are evidence-based, secure, and highly effective.
The opioid crisis, in accordance with the Canadian government, has brought to light the adverse consequences that opioids are having on individuals, families, and communities across Canada. More than 9,000 alleged opioid-related deaths have occurred since 2016. About 11 people per day died from opioid overdoses in 2017. Numerous individuals have required hospitalization due to an opioid overdose. A total of $359.2 million over five years has been funded in the budget for 2023 to fund the Canadian Drugs and Substances Strategy (CDSS). It adds to over $800 million spent fighting the overdose issue since 2017. It is predicted that the market for opioid use disorders will expand as the number of opioid addicts increases in the region.
The US market dominated the North America Opioid Use Disorder (OUD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,946.3 million by 2030. The Canada market is estimated to grow at a CAGR of 11.8% during (2023 - 2030). Additionally, The Mexico market would witness a CAGR of 10.8% during (2023 - 2030).
Based on Drug Class, the market is segmented into Buprenorphine, Methadone and Naltrexone. Based on Route of Administration, the market is segmented into Parenteral and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies & Stores and Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Indivior PLC (Reckitt Benckiser Group plc), Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.), Orexo AB (Orexo US, Inc.), Alkermes PLC, Titan Pharmaceuticals, Inc., Camurus AB, AstraZeneca PLC, Hikma Pharmaceuticals PLC, Mallinckrodt PLC, and Viatris, Inc.
Scope of the Study
Market Segments covered in the Report:
By Drug Class
- Buprenorphine
- Methadone
- Naltrexone
By Route of Administration
- Parenteral
- Oral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
By Country
- US
- Canada
- Mexico
- Rest of North America
Companies Profiled
- Indivior PLC (Reckitt Benckiser Group plc)
- Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- Orexo AB (Orexo US, Inc.)
- Alkermes PLC
- Titan Pharmaceuticals, Inc.
- Camurus AB
- AstraZeneca PLC
- Hikma Pharmaceuticals PLC
- Mallinckrodt PLC
- Viatris, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 North America Opioid Use Disorder (OUD) Market, by Drug Class
- 1.4.2 North America Opioid Use Disorder (OUD) Market, by Route of Administration
- 1.4.3 North America Opioid Use Disorder (OUD) Market, by Distribution Channel
- 1.4.4 North America Opioid Use Disorder (OUD) Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition and Scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market
Chapter 4. North America Opioid Use Disorder (OUD) Market by Drug Class
- 4.1 North America Buprenorphine Market by Country
- 4.2 North America Methadone Market by Country
- 4.3 North America Naltrexone Market by Country
Chapter 5. North America Opioid Use Disorder (OUD) Market by Route of Administration
- 5.1 North America Parenteral Market by Country
- 5.2 North America Oral Market by Country
Chapter 6. North America Opioid Use Disorder (OUD) Market by Distribution Channel
- 6.1 North America Hospital Pharmacies Market by Country
- 6.2 North America Retail Pharmacies & Stores Market by Country
- 6.3 North America Online Pharmacies Market by Country
Chapter 7. North America Opioid Use Disorder (OUD) Market by Country
- 7.1 US Opioid Use Disorder (OUD) Market
- 7.1.1 US Opioid Use Disorder (OUD) Market by Drug Class
- 7.1.2 US Opioid Use Disorder (OUD) Market by Route of Administration
- 7.1.3 US Opioid Use Disorder (OUD) Market by Distribution Channel
- 7.2 Canada Opioid Use Disorder (OUD) Market
- 7.2.1 Canada Opioid Use Disorder (OUD) Market by Drug Class
- 7.2.2 Canada Opioid Use Disorder (OUD) Market by Route of Administration
- 7.2.3 Canada Opioid Use Disorder (OUD) Market by Distribution Channel
- 7.3 Mexico Opioid Use Disorder (OUD) Market
- 7.3.1 Mexico Opioid Use Disorder (OUD) Market by Drug Class
- 7.3.2 Mexico Opioid Use Disorder (OUD) Market by Route of Administration
- 7.3.3 Mexico Opioid Use Disorder (OUD) Market by Distribution Channel
- 7.4 Rest of North America Opioid Use Disorder (OUD) Market
- 7.4.1 Rest of North America Opioid Use Disorder (OUD) Market by Drug Class
- 7.4.2 Rest of North America Opioid Use Disorder (OUD) Market by Route of Administration
- 7.4.3 Rest of North America Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 8. Company Profiles
- 8.1 Indivior PLC (Reckitt Benckiser Group plc)
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Product and Regional Analysis
- 8.1.4 Research & Development Expenses
- 8.1.5 Recent strategies and developments:
- 8.1.5.1 Partnerships, Collaborations, and Agreements:
- 8.1.5.2 Acquisition and Mergers:
- 8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Research & Development Expenses
- 8.3 Orexo AB (Orexo US, Inc.)
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Segmental and Regional Analysis
- 8.3.4 Research & Development Expenses
- 8.3.5 Recent strategies and developments:
- 8.3.5.1 Partnerships, Collaborations, and Agreements:
- 8.4 Alkermes PLC
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expenses
- 8.4.5 Recent strategies and developments:
- 8.4.5.1 Trials and Approvals:
- 8.5 Titan Pharmaceuticals, Inc.
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Segmental and Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
- 8.5.5.1 Trials and Approvals:
- 8.6 Camurus AB
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental and Regional Analysis
- 8.6.4 Research & Development Expenses
- 8.6.5 Recent strategies and developments:
- 8.6.5.1 Partnerships, Collaborations, and Agreements:
- 8.6.5.2 Trials and Approvals:
- 8.7 AstraZeneca PLC
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Regional Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 Recent strategies and developments:
- 8.7.5.1 Acquisition and Mergers:
- 8.8 Hikma Pharmaceuticals PLC
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expenses
- 8.8.5 Recent strategies and developments:
- 8.8.5.1 Product Launches and Product Expansions:
- 8.9 Mallinckrodt PLC
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Segmental and Regional Analysis
- 8.9.4 Research & Development Expense
- 8.10. Viatris, Inc.
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Segmental Analysis
- 8.10.4 Research & Development Expense
LIST OF TABLES
- TABLE 1 North America Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
- TABLE 2 North America Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
- TABLE 3 North America Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
- TABLE 4 North America Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
- TABLE 5 North America Buprenorphine Market by Country, 2019 - 2022, USD Million
- TABLE 6 North America Buprenorphine Market by Country, 2023 - 2030, USD Million
- TABLE 7 North America Methadone Market by Country, 2019 - 2022, USD Million
- TABLE 8 North America Methadone Market by Country, 2023 - 2030, USD Million
- TABLE 9 North America Naltrexone Market by Country, 2019 - 2022, USD Million
- TABLE 10 North America Naltrexone Market by Country, 2023 - 2030, USD Million
- TABLE 11 North America Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 12 North America Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
- TABLE 13 North America Parenteral Market by Country, 2019 - 2022, USD Million
- TABLE 14 North America Parenteral Market by Country, 2023 - 2030, USD Million
- TABLE 15 North America Oral Market by Country, 2019 - 2022, USD Million
- TABLE 16 North America Oral Market by Country, 2023 - 2030, USD Million
- TABLE 17 North America Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 18 North America Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 19 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 20 North America Hospital Pharmacies Market by Country, 2023 - 2030, USD Million
- TABLE 21 North America Retail Pharmacies & Stores Market by Country, 2019 - 2022, USD Million
- TABLE 22 North America Retail Pharmacies & Stores Market by Country, 2023 - 2030, USD Million
- TABLE 23 North America Online Pharmacies Market by Country, 2019 - 2022, USD Million
- TABLE 24 North America Online Pharmacies Market by Country, 2023 - 2030, USD Million
- TABLE 25 North America Opioid Use Disorder (OUD) Market by Country, 2019 - 2022, USD Million
- TABLE 26 North America Opioid Use Disorder (OUD) Market by Country, 2023 - 2030, USD Million
- TABLE 27 US Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
- TABLE 28 US Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
- TABLE 29 US Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
- TABLE 30 US Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
- TABLE 31 US Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 32 US Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
- TABLE 33 US Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 34 US Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 35 Canada Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
- TABLE 36 Canada Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
- TABLE 37 Canada Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
- TABLE 38 Canada Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
- TABLE 39 Canada Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 40 Canada Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
- TABLE 41 Canada Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 42 Canada Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 43 Mexico Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
- TABLE 44 Mexico Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
- TABLE 45 Mexico Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
- TABLE 46 Mexico Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
- TABLE 47 Mexico Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 48 Mexico Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
- TABLE 49 Mexico Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 50 Mexico Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 51 Rest of North America Opioid Use Disorder (OUD) Market, 2019 - 2022, USD Million
- TABLE 52 Rest of North America Opioid Use Disorder (OUD) Market, 2023 - 2030, USD Million
- TABLE 53 Rest of North America Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2022, USD Million
- TABLE 54 Rest of North America Opioid Use Disorder (OUD) Market by Drug Class, 2023 - 2030, USD Million
- TABLE 55 Rest of North America Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2022, USD Million
- TABLE 56 Rest of North America Opioid Use Disorder (OUD) Market by Route of Administration, 2023 - 2030, USD Million
- TABLE 57 Rest of North America Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2022, USD Million
- TABLE 58 Rest of North America Opioid Use Disorder (OUD) Market by Distribution Channel, 2023 - 2030, USD Million
- TABLE 59 Key Information - Indivior PLC (Reckitt Benckiser Group plc)
- TABLE 60 Key Information - collegium pharmaceutical
- TABLE 61 Key Information - Orexo AB
- TABLE 62 Key Information - Alkermes PLC
- TABLE 63 Key Information - Titan Pharmaceuticals, Inc.
- TABLE 64 Key Information - Camurus AB
- TABLE 65 KEY INFORMATION - AstraZeneca PLC
- TABLE 66 Key Information - Hikma Pharmaceuticals PLC
- TABLE 67 Key information - Mallinckrodt PLC
- TABLE 68 key information - Viatris, Inc.
List of Figures
- FIG 1 Methodology for the research
- FIG 2 North America Opioid Use Disorder (OUD) Market share by Drug Class, 2022
- FIG 3 North America Opioid Use Disorder (OUD) Market share by Drug Class, 2030
- FIG 4 North America Opioid Use Disorder (OUD) Market by Drug Class, 2019 - 2030, USD Million
- FIG 5 North America Opioid Use Disorder (OUD) Market share by Route of Administration, 2022
- FIG 6 North America Opioid Use Disorder (OUD) Market share by Route of Administration, 2030
- FIG 7 North America Opioid Use Disorder (OUD) Market by Route of Administration, 2019 - 2030, USD Million
- FIG 8 North America Opioid Use Disorder (OUD) Market share by Distribution Channel, 2022
- FIG 9 North America Opioid Use Disorder (OUD) Market share by Distribution Channel, 2030
- FIG 10 North America Opioid Use Disorder (OUD) Market by Distribution Channel, 2019 - 2030, USD Million
- FIG 11 North America Opioid Use Disorder (OUD) Market share by Country, 2022
- FIG 12 North America Opioid Use Disorder (OUD) Market share by Country, 2030
- FIG 13 North America Opioid Use Disorder (OUD) Market by Country, 2019 - 2030, USD Million
